| USD ($) $ in Millions, shares in Millions | LTM | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 | Dec 31, 2011 | Dec 31, 2010 | Dec 31, 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenues | ||||||||||||||||||
Product revenues | - | - | - | - | ||||||||||||||
Service revenues | - | - | - | - | ||||||||||||||
Total revenues | 46,336 | 44,556 | 42,879 | 42,857 | ||||||||||||||
Costs and operating expenses: | ||||||||||||||||||
Cost of product revenues | - | - | - | - | ||||||||||||||
Cost of service revenues | - | - | - | - | ||||||||||||||
Selling, general and administrative expenses | 9,028 | 8,732 | 8,595 | 8,445 | ||||||||||||||
Research and development expenses | 1,402 | 1,397 | 1,390 | 1,337 | ||||||||||||||
Restructuring and other costs | 329 | 362 | 379 | 459 | ||||||||||||||
Total costs and operating expenses | 38,191 | 36,810 | 35,542 | 35,998 | ||||||||||||||
Operating income | 8,145 | 7,746 | 7,337 | 6,859 | ||||||||||||||
Interest income | 932 | 993 | 1,078 | 879 | ||||||||||||||
Interest expense | (1,467) | (1,419) | (1,390) | (1,375) | ||||||||||||||
Other income/(expense) | 26 | (12) | 12 | (65) | ||||||||||||||
Income before income taxes | 7,637 | 7,308 | 7,037 | 6,298 | ||||||||||||||
Other Expense, Net | - | - | - | - | ||||||||||||||
Benefit from/(provision for) income taxes | 598 | 547 | 657 | 284 | ||||||||||||||
Equity in earnings/(losses) of unconsolidated entities | (52) | (41) | (42) | (59) | ||||||||||||||
Net income | 6,988 | 6,721 | 6,338 | 5,955 | ||||||||||||||
Less: net income/(loss) attributable to noncontrolling interests and redeemable noncontrolling interest | 21 | 17 | 3 | (40) | ||||||||||||||
Net income attributable to Thermo Fisher Scientific Inc. | 6,967 | 6,704 | 6,335 | 5,995 | ||||||||||||||
Income from Continuing Operations | - | - | - | - | ||||||||||||||
Loss from Discontinued Operations (net of income tax benefit of $0, $0 and $2) | - | - | - | - | ||||||||||||||
Loss from Discontinued Operations (net of income tax benefit of $0.6, $0.5 and $10.8) | - | - | - | - | ||||||||||||||
Loss on Disposal of Discontinued Operations, Net (net of income tax benefit of $3.2 and $33.2) | - | - | - | - | ||||||||||||||
Earnings per Share from Continuing Operations | ||||||||||||||||||
Basic (in dollars per share) | - | - | - | - | ||||||||||||||
Diluted (in dollars per share) | - | - | - | - | ||||||||||||||
Earnings per share attributable to Thermo Fisher Scientific Inc. | ||||||||||||||||||
Basic (in dollars per share) | 18.61 | 17.77 | 16.58 | 15.52 | ||||||||||||||
Diluted (in dollars per share) | 18.58 | 17.74 | 16.53 | 15.45 | ||||||||||||||
Weighted average shares | ||||||||||||||||||
Basic (in shares) | 372 | 377 | 382 | 386 | ||||||||||||||
Diluted (in shares) | 372 | 378 | 383 | 388 | ||||||||||||||
Cash Dividends Declared per Common Share (in dollars per share) | - | - | - | - |